Leprosy in the Era of Zero-Leprosy Targets: Pathobiology, Clinical Care, Prevention, and Implementation Priorities
Al Makki Health Informatics Journal · 25.01.2026 · 4 (1) · 26-39
DOI: 10.57185/a3dk2q86 ↗Kurz gefasst
Fachartikel in der Zeitschrift Al Makki Health Informatics Journal, online erschienen am 25.01.2026. Verfasst von Renni Yuniati und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Leprosy (Hansen disease) is a chronic infectious disease caused predominantly by Mycobacterium leprae and, in a smaller number of cases, Mycobacterium lepromatosis. Although multidrug therapy (MDT) has made leprosy curable and has markedly reduced prevalence, approximately 200,000 new cases are reported annually, with Brazil, India, and Indonesia carrying the largest burdens. This narrative review synthesizes World Health Organization guidance and peer-reviewed literature published between 2018 and 2026, with seminal older sources retained, identified in PubMed, Scopus, WHO IRIS, Google Scholar, and the Indonesian databases Garuda and SINTA, to map the distance between biomedical cure and programme-level elimination. Clinical expression is heterogeneous because host immunity determines the balance between bacillary control, inflammation, and nerve injury. Diagnosis remains primarily clinical and is anchored by three cardinal signs. The main therapeutic regimen is rifampicin, dapsone, and clofazimine for 6 months in paucibacillary disease and 12 months in multibacillary disease. However, MDT alone is insufficient to interrupt transmission or prevent disability. Contact screening, single-dose rifampicin post-exposure prophylaxis, active case finding, early recognition of neuritis and leprosy reactions, rehabilitation, and stigma reduction are necessary components of a contemporary control programme. Its distinctive contribution is an explicit Indonesia-focused implementation perspective linking national epidemiological data, detection delay, and stigma to measurable programme indicators. Priority research areas include field-ready diagnostics, surveillance of antimicrobial resistance, predictive biomarkers for nerve injury, and delivery models that integrate affected persons and communities into prevention and care.
Zitieren
APA
Yuniati, R., Hidayati, F. C., & Haq, M. A. (2026). Leprosy in the Era of Zero-Leprosy Targets: Pathobiology, Clinical Care, Prevention, and Implementation Priorities. Al Makki Health Informatics Journal, 4(1), 26-39. https://doi.org/10.57185/a3dk2q86
Vancouver
Yuniati R, Hidayati FC, Haq MA. Leprosy in the Era of Zero-Leprosy Targets: Pathobiology, Clinical Care, Prevention, and Implementation Priorities. Al Makki Health Informatics Journal. 2026;4(1):26-39. doi:10.57185/a3dk2q86
BibTeX
@article{Yuniati2026,
author = {Yuniati, Renni and Hidayati, Farah Chilwa and Haq, Muhammad Auzi’nal},
title = {Leprosy in the Era of Zero-Leprosy Targets: Pathobiology, Clinical Care, Prevention, and Implementation Priorities},
journal = {Al Makki Health Informatics Journal},
year = {2026},
volume = {4},
number = {1},
pages = {26--39},
doi = {10.57185/a3dk2q86}
}
EUVIMED